DPP4 and hydrops fetalis: A meta-analysiscombining the data from the SAVOR, EXAMINE, and TECOS trials showed that the risk ofHHF in the DPP4 inhibitor group had not increased (623 cases of HF in the DPP4inhibitor group vs. 546 in the placebo group; HR, 1.14; 95% CI, 0.97 to 1.34)14.